Related Experiment Video
Updated: Jun 23, 2026
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
[Effect of a novel fibrinolytic enzyme FA-I on thrombosis and thrombolysis]
Gao-xue Wang1, Chao-jun Liang, Jia-yun Yao
1College of Animal Science and Technology, Northwest A&F University, Yangling 712100, China.
Objective:
To study the effect of FA-I, a novel fibrinolytic enzyme isolated from the metabolite of Arthrobacter sp. DR-536, on thrombosis and thrombolysis in vivo.
Methods:
The anticoagulated blood model of mise were administered with FA-I orally. The venous thrombogenesis inhibition model of rats were administered with FA-I by intestinal route. The carotid thrombosis model of rabbits were given FA-I intravenously. The clotting time (CT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), Euglobulin lysis time (ELT), fibrinogen (FIG) and hemorheology condition were analyzed.
Results:
FA-I prolonged the CT, PT, APTT and TT, and decreased ELT and FIG significantly (P < 0.05 or P < 0.01). FA-I also improved the hemorheology conditions in the rabbits.
Conclusion:
Both intravenous injection and oral administration of FA-I are effective in thrombosis and thrombolysis. FA-I could become a pragmatic venoclysis thrombolytic drug or a peroral thrombolytic drug.
Insights
FA-I, a novel fibrinolytic enzyme, effectively prevents thrombosis and promotes thrombolysis in vivo. Both intravenous and oral administration show significant therapeutic potential for treating blood clots.
Area of Science:
- Biochemistry
- Pharmacology
- Microbiology
Context:
- Thrombosis and thrombolysis are critical clinical challenges.
- Fibrinolytic enzymes offer therapeutic potential for thrombotic disorders.
- Novel enzyme discovery from microbial sources is an active research area.
Purpose:
- To investigate the in vivo effects of FA-I, a novel fibrinolytic enzyme from Arthrobacter sp. DR-536, on thrombosis and thrombolysis.
- To evaluate the efficacy of FA-I following different administration routes (oral, intestinal, intravenous).
Summary:
- FA-I administration (oral, intestinal, intravenous) significantly prolonged clotting time (CT), prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT).
- FA-I treatment markedly reduced Euglobulin lysis time (ELT) and fibrinogen (FIG) levels, indicating enhanced fibrinolysis.
- The enzyme also demonstrated positive effects on hemorheology in rabbit models.
Impact:
- FA-I exhibits dual efficacy in preventing thrombosis and promoting thrombolysis.
- Results suggest FA-I's potential as a novel therapeutic agent for thrombotic conditions.
- The study highlights the promise of microbial-derived enzymes in developing new anticoagulant and thrombolytic drugs.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...